Dual HER2 Suppression with Lapatinib plus Trastuzumab for Metastatic Inflammatory Breast Cancer: A Case Report of Prolonged Stable Disease.

ABSTRACT:

Background

Continuous therapy targeting human epidermal growth factor receptor 2 (HER2) is recommended until disease progression for patients with HER2-overexpressing (HER2+) metastatic breast cancer. Prolonged stable disease has been observed with such maintenance therapy using trastuzumab, but the frequency of these cases remains low. Whether combined maintenance therapy with two different HER2-targeted agents could improve the rates of durable progression-free survival compared with trastuzumab alone is under investigation.

Objectives

To evaluate the efficacy of the combined HER2-targeted agents, trastuzumab and lapatinib, as maintenance therapy in one patient.

Methods

We describe a patient with HER2+, hormone receptor-negative, inflammatory metastatic breast cance

SUBMITTER: Ogawa L 

PROVIDER: S-EPMC6341317 | biostudies-literature | 2018 Sep-Dec

REPOSITORIES: biostudies-literature